Delayed emptying is not the diagnosis
GLP-1 physiology and gastroparesis should not be treated as interchangeable terms
Current semaglutide and tirzepatide labels state that these medicines delay gastric emptying. NIDDK explains that medicines that delay emptying or affect motility can produce symptoms similar to gastroparesis and may worsen symptoms in someone already diagnosed. Gastroparesis itself is a clinical disorder that requires medical assessment; a social-media symptom list, one episode of nausea, or the known pharmacologic effect of a GLP-1 does not establish the diagnosis, its severity, or its cause.
- Tell the clinician whether fullness, nausea, vomiting, bloating, belching, reflux, upper-abdominal discomfort, appetite change, constipation, or weight change is new, persistent, worsening, or linked to a treatment change.
- Do not assume every stomach symptom is gastroparesis; infection, obstruction, gallbladder or pancreatic disease, medication effects, diabetes, constipation, pregnancy, and other causes may need consideration.
- Do not use a seller page or forum to label symptoms as permanent, reversible, mild, or severe without an individualized evaluation.
Current branded-label warning
Wegovy, Ozempic, Zepbound, and Mounjaro are not recommended in severe gastroparesis
The current manufacturer prescribing information for Wegovy, Ozempic injection, semaglutide tablets sold under the Ozempic/Rybelsus label set, Zepbound, and Mounjaro states that each product is not recommended in patients with severe gastroparesis. The labels also describe sometimes-severe gastrointestinal adverse reactions. This wording is not a universal diagnostic threshold, a personal risk percentage, or an instruction for patients to stop treatment independently. It is a product-specific prescribing warning that makes accurate history, symptom review, and clinician judgment important before starting or continuing care.
- Share any prior gastroparesis diagnosis, gastric-emptying test, unexplained vomiting, retained food, feeding support, severe reflux, motility disorder, or previous hospitalization before a prescribing decision.
- Ask the prescriber how “severe” is being assessed for your history and which symptoms or findings would change the treatment plan.
- Do not transfer one branded label into a dosing, hold, restart, or switching rule for every GLP-1 product or every patient-specific compounded preparation.
Symptoms and urgent warning signs
Persistent vomiting, dehydration, severe pain, or systemic illness needs prompt assessment
NIDDK lists early or prolonged fullness, nausea, vomiting, bloating, belching, upper-abdominal pain, heartburn, and poor appetite among possible gastroparesis symptoms. These symptoms overlap with common GLP-1 effects and other illnesses, so duration, severity, food and fluid tolerance, bowel function, glucose, vital signs, and the complete medication list matter. A clinician should assess concerning patterns rather than having the patient simply wait for a routine follow-up or treat the symptom from an online recipe.
- Seek prompt medical help for repeated vomiting, inability to keep fluids down, markedly reduced urination, fainting, confusion, severe weakness, trouble breathing, fever, blood or coffee-ground material in vomit, or signs of significant dehydration.
- Severe or persistent abdominal pain, a swollen or rigid abdomen, inability to pass stool or gas, chest pain, or serious high- or low-glucose symptoms also needs urgent evaluation.
- Contact the responsible clinician before the next treatment decision when symptoms persist, oral intake falls, weight changes rapidly, medicines cannot be kept down, or the diagnosis is uncertain.
Diagnosis and testing
Symptoms alone cannot measure stomach emptying or rule out another cause
NIDDK describes diagnosis as a combination of medical history, physical examination, symptoms, and medical tests. Evaluation may include laboratory tests, upper-GI endoscopy, imaging, and a test that measures stomach emptying. Gastric-emptying scintigraphy is one established method, but the responsible clinician decides which test is appropriate and how medicines, glucose, prior surgery, and other conditions affect preparation and interpretation. An online page cannot determine whether testing is needed or interpret one result in isolation.
- Bring the exact product, route, pharmacy label, start and change dates, last use, symptom timeline, diabetes history, glucose pattern, prior procedures, and all prescriptions and supplements.
- Ask which alternative causes need to be excluded and whether a gastroenterology, diabetes, nutrition, or medication-management referral is appropriate.
- Do not self-order a nonstandard test, alter medicines to prepare for testing, or copy a gastric-emptying cutoff without instructions from the testing team.
Injection, tablet, and compounded identity
The exact product and route matter even when the active ingredient is similar
This guide focuses mainly on semaglutide and tirzepatide injections, including Wegovy, Ozempic injection, Zepbound, Mounjaro, and clinician-directed compounded prescriptions. Current official records also include labeled semaglutide tablets within the Wegovy and combined Ozempic/Rybelsus label sets. A patient-specific compounded semaglutide or tirzepatide preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, container, directions, pharmacy labeling, storage, and clinical context. Route and product identity must be verified rather than inferred from a nickname.
- Show the actual carton, pen, vial, bottle, or pharmacy label and name the active ingredient, route, indication, prescriber, dispensing pharmacy, and other ingredients.
- Report insulin, sulfonylureas, opioids, anticholinergic medicines, constipation treatments, supplements, and oral medicines whose absorption or effect may require monitoring.
- Reject research-use products, no-prescription sellers, hidden pharmacies, copied syringe conversions, and claims that a compounded preparation is FDA-approved Wegovy, Ozempic, Zepbound, or Mounjaro.
Clinician-directed next step
Do not self-hold or restart a GLP-1 while a serious stomach problem is being evaluated
The next step depends on the exact product, indication, symptom severity, hydration and nutrition, glucose risk, other medicines, prior diagnosis, and clinician assessment. Stopping or restarting can create separate missed-dose, glucose, and tolerance questions, while continuing through severe symptoms can also be unsafe. Contact the prescribing team for a written plan and use urgent care when warning signs are present; do not double, split, stretch, taper, switch, or resume treatment from a generic online schedule.
- Ask who owns the decision—the GLP-1 prescriber, diabetes clinician, gastroenterologist, primary-care clinician, pharmacist, or urgent-care team—and how they will coordinate.
- If a procedure with anesthesia or deep sedation is planned, disclose the exact GLP-1 and active gastrointestinal symptoms to the procedure team early.
- Ask how oral medicines, glucose monitoring, hydration, nutrition, follow-up, and any future treatment change should be handled while the cause is being assessed.